Switch theme
Sign up to access all valuation multiples
Imricor Medical Systems Inc is a medical device company engaged in addressing issues with traditional x-ray-guided ablation procedures through the development of MRI-guided technology. Its principal business activities are to design, manufacture and sell MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The products of the company include Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter and Vision-MR Dispersive Electrode.
2006
n/a
LTM Revenue $2.5M
LTM EBITDA -$23.6M
$247M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Imricor Medical Systems has a last 12-month revenue of $2.5M and a last 12-month EBITDA of -$23.6M.
In the most recent fiscal year, Imricor Medical Systems achieved revenue of $0.4M and an EBITDA of -$13.8M.
Imricor Medical Systems expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Imricor Medical Systems valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.5M | $0.4M | XXX | XXX | XXX |
| Gross Profit | -$1.2M | -$1.0M | XXX | XXX | XXX |
| Gross Margin | -232% | -248% | XXX | XXX | XXX |
| EBITDA | -$10.4M | -$13.8M | XXX | XXX | XXX |
| EBITDA Margin | -2018% | -3553% | XXX | XXX | XXX |
| Net Profit | -$12.5M | -$11.0M | XXX | XXX | XXX |
| Net Margin | -2418% | -2820% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Imricor Medical Systems's stock price is AUD 1 (or $1).
Imricor Medical Systems has current market cap of AUD 381M (or $241M), and EV of AUD 390M (or $247M).
See Imricor Medical Systems trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $247M | $241M | XXX | XXX | XXX | XXX | $-0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Imricor Medical Systems has market cap of $241M and EV of $247M.
Imricor Medical Systems's trades at 153.8x LTM EV/Revenue multiple, and -16.5x LTM EBITDA.
Analysts estimate Imricor Medical Systems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Imricor Medical Systems and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $247M | XXX | XXX | XXX |
| EV/Revenue | 633.4x | XXX | XXX | XXX |
| EV/EBITDA | -17.8x | XXX | XXX | XXX |
| P/E | -16.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -29.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpImricor Medical Systems's NTM/LTM revenue growth is 330%
Imricor Medical Systems's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Imricor Medical Systems's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Imricor Medical Systems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Imricor Medical Systems and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -25% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -3553% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -3223% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 444% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 827% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1287% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2674% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Imricor Medical Systems acquired XXX companies to date.
Last acquisition by Imricor Medical Systems was XXXXXXXX, XXXXX XXXXX XXXXXX . Imricor Medical Systems acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Imricor Medical Systems founded? | Imricor Medical Systems was founded in 2006. |
| Where is Imricor Medical Systems headquartered? | Imricor Medical Systems is headquartered in Australia. |
| Is Imricor Medical Systems publicy listed? | Yes, Imricor Medical Systems is a public company listed on ASX. |
| What is the stock symbol of Imricor Medical Systems? | Imricor Medical Systems trades under IMR ticker. |
| When did Imricor Medical Systems go public? | Imricor Medical Systems went public in 2019. |
| Who are competitors of Imricor Medical Systems? | Similar companies to Imricor Medical Systems include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Imricor Medical Systems? | Imricor Medical Systems's current market cap is $241M |
| What is the current revenue of Imricor Medical Systems? | Imricor Medical Systems's last 12-month revenue is $2.5M. |
| What is the current EBITDA of Imricor Medical Systems? | Imricor Medical Systems's last 12-month EBITDA is -$23.6M. |
| What is the current EV/Revenue multiple of Imricor Medical Systems? | Current revenue multiple of Imricor Medical Systems is 153.8x. |
| What is the current EV/EBITDA multiple of Imricor Medical Systems? | Current EBITDA multiple of Imricor Medical Systems is -16.5x. |
| What is the current revenue growth of Imricor Medical Systems? | Imricor Medical Systems revenue growth between 2023 and 2024 was -25%. |
| Is Imricor Medical Systems profitable? | Yes, Imricor Medical Systems is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
